Lucidenic acid D  (Synonyms: Lucidenic acid D2)

Lucidenic acid D is a highly oxidized triterpenoid with anti-inflammatory and antiviral activities. Lucidenic acid D attenuates lipopolysaccharide-induced release of proinflammatory cytokines and nitric oxide, reduces the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), and inhibits skin inflammation. Lucidenic acid D suppresses 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced expression of Epstein-Barr virus (EBV) early antigen and maintains the viability of Raji cells. Lucidenic acid D can be used in studies of cancer chemoprevention^[1][2][3][4].

Lucidenic acid D (as methyl lucidenate D) is a new highly oxidized lanostane-type triterpenoid isolated from Ganoderma lucidum gills, with its structure elucidated using spectral evidence including mass spectrometry, ¹H-NMR, and ¹³C-NMR^[1].
Lucidenic acid D inhibits Epstein-Barr virus early antigen activation in Raji cells^[2].
Lucidenic acid D (10, 50 μg/mL; 30 min) does not alter LPS-induced p38 or JNK phosphorylation in THP-1 cells^[3].
Lucidenic acid D (50 μg/mL; 4 h) does not significantly enhance LPS-induced TNFα mRNA expression in THP-1 cells^[3].
Lucidenic acid D₂ (10-1000 mol ratio/TPA; 48 h) potently inhibits EBV-EA activation in Raji cells, with an IC₅₀ of 287 mol ratio/TPA, and maintains 70% cell viability at the highest tested concentration^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

514.61

C₂₉H₃₈O₈

98665-16-8

Solid

Off-white to yellow

C[C@@]([C@@H]1OC(C)=O)([C@@](C2)([H])[C@H](C)CCC(O)=O)[C@](C(C(C[C@@]3([H])C4(C)C)=O)=C([C@]3(CCC4=O)C)C1=O)(C2=O)C

Room temperature in continental US; may vary elsewhere.

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

• [1]. Tohru Kikuchi, et al. GANODERIC ACID D, E, F, AND H AND LUCIDENIC ACID D, E, AND F, NEW TRITERPENOIDS FROM GANODERMA LUCIDUM. Chem Pharm Bull. 1985, 33 (6): 2624-2627.

  [2]. Zheng C, et al. A Review on the Sources, Structures, and Pharmacological Activities of Lucidenic Acids. Molecules. 2023;28(4):1756. Published 2023 Feb 12.  [Content Brief]

  [3]. Watanabe K, et al. Lucidenic acids-rich extract from antlered form of Ganoderma lucidum enhances TNFα induction in THP-1 monocytic cells possibly via its modulation of MAP kinases p38 and JNK. Biochem Biophys Res Commun. 2011;408(1):18-24.  [Content Brief]

  [4]. Iwatsuki K, et al. Lucidenic acids P and Q, methyl lucidenate P, and other triterpenoids from the fungus Ganoderma lucidum and their inhibitory effects on Epstein-Barr virus activation. J Nat Prod. 2003;66(12):1582-1585.  [Content Brief]